REPAIR: Right vEntricular Remodeling in Pulmonary ArterIal hypeRtension
Status:
Completed
Trial end date:
2019-09-10
Target enrollment:
Participant gender:
Summary
The study evaluates the effect of macitentan on right ventricular and hemodynamic properties
in patients with symptomatic pulmonary arterial hypertension. Patients are treated with
macitentan for 1 year. Patients undergo right heart catheterization (RHC) at baseline and
Week 26. They also undergo cardiac magnetic resonance imaging (MRI) at baseline, Week 26 and
Week 52. Safety is monitored throughout the study. The study has three stub-studies. Each
patient can participate in no sub-study or in one sub-study. The sub-studies are: (1)
metabolism sub-study (with PET-MR scans); (2) biopsy sub-study (biopsies taken during the
RHC); (3) Echo sub-study.